These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31718296)

  • 1. Do Risk-Enhancing Factors Enhance Risk Estimation?
    Stern RH; Brook RD
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006078. PubMed ID: 31718296
    [No Abstract]   [Full Text] [Related]  

  • 2. AHA/ACC/Multisociety Cholesterol Guidelines: highlights.
    Jialal I; Devaraj S
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719881579. PubMed ID: 31590600
    [No Abstract]   [Full Text] [Related]  

  • 3. The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components.
    Virani SS
    Tex Heart Inst J; 2016 Aug; 43(4):313-4. PubMed ID: 27547139
    [No Abstract]   [Full Text] [Related]  

  • 4. It's never too early to beat your low-density lipoprotein cholesterol.
    Bergerot C; Angoulvant D; Lemesle G; Barone-Rochette G; Mewton N; Mach F
    Arch Cardiovasc Dis; 2021 Jan; 114(1):1-3. PubMed ID: 33509745
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid update 2020 - Introduction and foreword.
    Robinson JG
    Prog Cardiovasc Dis; 2019; 62(5):373-374. PubMed ID: 31711789
    [No Abstract]   [Full Text] [Related]  

  • 6. Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines.
    Robinson JG; Ray K
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):586-90. PubMed ID: 26988588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The New 2018 Cholesterol Guidelines.
    Khera A
    Circulation; 2019 Jun; 139(25):2805-2808. PubMed ID: 30586686
    [No Abstract]   [Full Text] [Related]  

  • 8. The systematic coronary risk evaluation (SCORE) for the prevention of cardiovascular diseases. Does evidence exist for its effectiveness? A systematic review.
    Tomasik T; Krzysztoń J; Dubas-Jakóbczyk K; Kijowska V; Windak A
    Acta Cardiol; 2017 Aug; 72(4):370-379. PubMed ID: 28705107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins.
    Ratchford EV; Martin SS
    Vasc Med; 2017 Oct; 22(5):442-445. PubMed ID: 28803537
    [No Abstract]   [Full Text] [Related]  

  • 10. LDL cholesterol: How low to go?
    Packard CJ
    Trends Cardiovasc Med; 2018 Jul; 28(5):348-354. PubMed ID: 29336946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
    Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
    Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 13. Utility of repeat serum cholesterol measurements for assessment of cardiovascular risk in primary prevention.
    Angelow A; Schmidt CO; Dörr M; Chenot JF
    Eur J Prev Cardiol; 2016 Apr; 23(6):628-35. PubMed ID: 26170419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDL and Reverse Cholesterol Transport Biomarkers.
    Riggs KA; Rohatgi A
    Methodist Debakey Cardiovasc J; 2019; 15(1):39-46. PubMed ID: 31049148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2018 Guidelines for the management of dyslipidemia.
    Rhee EJ; Kim HC; Kim JH; Lee EY; Kim BJ; Kim EM; Song Y; Lim JH; Kim HJ; Choi S; Moon MK; Na JO; Park KY; Oh MS; Han SY; Noh J; Yi KH; Lee SH; Hong SC; Jeong IK
    Korean J Intern Med; 2019 Jul; 34(4):723-771. PubMed ID: 31272142
    [No Abstract]   [Full Text] [Related]  

  • 17. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?
    Banach M; Penson PE
    Cardiovasc Res; 2019 Mar; 115(3):e26-e31. PubMed ID: 30605511
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.
    Szarek M; Reijnders E; Steg PG; Jukema JW; Schwertfeger M; Bhatt DL; Bittner VA; Diaz R; Fazio S; Garon G; Goodman SG; Harrington RA; White HD; Zeiher AM; Cobbaert C; Schwartz GG
    Eur J Prev Cardiol; 2024 Aug; 31(10):e75-e78. PubMed ID: 38501249
    [No Abstract]   [Full Text] [Related]  

  • 19. Nonstatin Therapy for Dyslipidemia.
    Ahmed HM; Nissen SE
    Circ Res; 2018 Oct; 123(9):1036-1038. PubMed ID: 30355163
    [No Abstract]   [Full Text] [Related]  

  • 20. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Grundy SM; Stone NJ; Bailey AL; Beam C; Birtcher KK; Blumenthal RS; Braun LT; de Ferranti S; Faiella-Tommasino J; Forman DE; Goldberg R; Heidenreich PA; Hlatky MA; Jones DW; Lloyd-Jones D; Lopez-Pajares N; Ndumele CE; Orringer CE; Peralta CA; Saseen JJ; Smith SC; Sperling L; Virani SS; Yeboah J
    Circulation; 2019 Jun; 139(25):e1046-e1081. PubMed ID: 30565953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.